Juno Therapeutics
NEWS
Juno Therapeutics was acquired by Bristol-Myers Squibb in 2019.
While the focus has been on M&A activity, Venture Capital firms have been investing billions in Biotech companies in 2018.
The U.S. Food and Drug Administration stunned the company with a Refusal to File letter regarding its New Drug Application (NDA) for multiple sclerosis treatment ozanimod.
The passing of tax reform led most analysts to predict that 2018 will be a strong year for mergers and acquisitions.
Juno’s Hans Bishop will take home $287M after Celgene acquired his company.
We are still only in January and Celgene and Sanofi have already made a combined $20B in M&A deals.
Employees of Juno received a surprise in their Monday morning emails.
The announcement sent shares of Juno soaring more than 27 percent in pre-market trading to $86.26.
Investors and analysts have given it some thought and mostly think it’s a sensible acquisition.
The rumors have caused Juno’s stock to rocket more than 50 percent to $68.80 in premarket trading.
JOBS
IN THE PRESS